| Market Cap | 73.58M | P/E | - | EPS this Y | 66.30% | Ern Qtrly Grth | - |
| Income | -27.9M | Forward P/E | -4.05 | EPS next Y | 55.50% | 50D Avg Chg | 3.00% |
| Sales | 1.23M | PEG | - | EPS past 5Y | - | 200D Avg Chg | 3.00% |
| Dividend | N/A | Price/Book | 4.48 | EPS next 5Y | - | 52W High Chg | -51.00% |
| Recommedations | 2.00 | Quick Ratio | 3.92 | Shares Outstanding | 12.88M | 52W Low Chg | 39.00% |
| Insider Own | 10.78% | ROA | -62.24% | Shares Float | 11.23M | Beta | 0.37 |
| Inst Own | 2.57% | ROE | -142.16% | Shares Shorted/Prior | 734.78K/1.03M | Price | 3.48 |
| Gross Margin | 58.99% | Profit Margin | - | Avg. Volume | 168,116 | Target Price | 8.32 |
| Oper. Margin | -747.86% | Earnings Date | - | Volume | 18,934 | Change | 3.88% |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
| HC Wainwright & Co. | Buy | Sep 4, 24 |
| Maxim Group | Buy | Aug 27, 24 |
| HC Wainwright & Co. | Buy | Aug 15, 24 |
| HC Wainwright & Co. | Buy | Jul 31, 24 |
| HC Wainwright & Co. | Buy | Jul 29, 24 |
| HC Wainwright & Co. | Buy | May 17, 24 |
| HC Wainwright & Co. | Buy | Apr 29, 24 |
| HC Wainwright & Co. | Buy | Dec 4, 23 |
| EF Hutton | Buy | May 16, 23 |
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Ross Cathy | Director Director | Jan 10 | Buy | 1.3089 | 5,000 | 6,544 | 10,000 | 01/11/24 |
| Baluch Khoso | Director Director | Dec 28 | Buy | 1.41 | 10,000 | 14,100 | 15,000 | 01/02/24 |
| Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Sep 21 | Option | 3.00 | 5,000 | 15,000 | 7,828,263 | 09/22/23 |
| Lehr Paul T | General Counsel, Sec.. General Counsel, Secretary | Sep 20 | Option | 3.00 | 2,000 | 6,000 | 144,213 | 09/21/23 |
| Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Sep 12 | Option | 3.00 | 30,000 | 90,000 | 7,823,263 | 09/14/23 |
| Soffer Rock | Director Director | Sep 08 | Option | 3.00 | 30,000 | 90,000 | 702,351 | 09/12/23 |
| Clavijo James | CFO and Treasurer CFO and Treasurer | Jun 27 | Sell | 3.47 | 23,532 | 81,656 | 47,303 | 06/29/23 |
| Clavijo James | CFO and Treasurer CFO and Treasurer | Jun 03 | Sell | 8.26 | 36,955 | 305,248 | 79,619 | 06/07/22 |
| Soffer Rock | Director Director | May 20 | Sell | 7.78 | 19,500 | 151,710 | 672,351 | 05/24/22 |
| Hare Joshua | Chief Scientific Off.. Chief Scientific Officer | Apr 18 | Sell | 10 | 20,000 | 200,000 | 7,913,263 | 04/20/22 |
| Soffer Rock | Director Director | Oct 11 | Buy | 3.59 | 19,900 | 71,441 | 51,757 | 10/13/21 |